相关实验视频
Updated: Jan 13, 2026

07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.8K
IGF2BP2通过m6A-依赖的STAT1mRNA不稳定驱动甲状腺癌脱差
Rui Chen1, Yi-Xun Li1, Wei-Lin Lu1
1Department of Breast Surgery, the First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, 210029, Nanjing, People's Republic of China.
International journal of biological sciences
|January 12, 2026
概括
通过向STAT1mRNA,IGF2BP2驱动甲状腺癌的脱差,从而导致侵袭性厌塑性甲状腺癌 (ATC). 这一发现为晚期甲状腺癌的再分化疗法提供了一个新的治疗标.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 甲状腺癌是一种常见的内分泌恶性瘤.
- 无塑性甲状腺癌 (ATC) 是一种激进的,致命的亚型,由非分化的乳头甲状腺癌 (PTC) 引起.
- 推动PTC脱差到ATC的分子机制在很大程度上是未知的.
研究的目的:
- 为了确定甲状腺癌脱差的分子驱动因素.
- 阐明这些驱动因素促进侵袭性瘤表型的机制.
- 为了确定晚期甲状腺癌的潜在治疗点.
主要方法:
- 基因表达的伪物质轨迹分析.
- 功能性测试评估细胞增殖,分化和癌症干性.
- 综合的多omics分析包括RNA-seq,RIP-seq和MeRIP-seq.
- 救援实验以验证机械学的发现.
主要成果:
- IGF2BP2在ATC上升调节,与预后不佳相关.
- IGF2BP2促进增殖,增强癌症干,并抑制甲状腺分化基因.
- IGF2BP2与m6A修饰的STAT1mRNA结合,促进其降解.
- STAT1对于IGF2BP2介导的甲状腺癌脱差至关重要.
结论:
- IGF2BP2-m6A-STAT1复合体是甲状腺癌脱差的一个关键调节器.
- 准这种复合体代表了在晚期甲状腺癌中重新分化治疗的新治疗策略.
相关概念视频
TGF - β Signaling Pathway
10.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K
Master Transcription Regulators
7.7K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.7K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K

